Journal
GENES
Volume 8, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/genes8020065
Keywords
minimized vector; antibiotic-free plasmid; miniplasmid; minicircle; minivector; DNA vaccine
Categories
Funding
- Baylor-University of Texas (UT) Houston Center [P30 AI036211]
- National Institutes of Health (NIH) [R56 AI054830, R01 GM115501]
Ask authors/readers for more resources
Uses of viral vectors have thus far eclipsed uses of non-viral vectors for gene therapy delivery in the clinic. Viral vectors, however, have certain issues involving genome integration, the inability to be delivered repeatedly, and possible host rejection. Fortunately, development of non-viral DNA vectors has progressed steadily, especially in plasmid vector length reduction, now allowing these tools to fill in specifically where viral or other non-viral vectors may not be the best options. In this review, we examine the improvements made to non-viral DNA gene therapy vectors, highlight opportunities for their further development, address therapeutic needs for which their use is the logical choice, and discuss their future expansion into the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available